id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-338251-r31xh0fw	Assi, Tarek	The management of patients with metastatic prostate cancer during the COVID-19 pandemic	2020-05-15		.txt	text/plain	4118	210	49	The STAMPEDE trial also compared abiraterone acetate and docetaxel in patients with mHSPC and showed no evidence of a difference in overall or prostate cancer-specific survival, or other important outcomes such as symptomatic skeletal events. Metastatic hormone-sensitive prostate cancer � In the metastatic hormone-sensitive prostate cancer setting, three antihormonal agents (apalutamide, enzalutamide and abiraterone acetate) and docetaxel were approved in addition to androgen deprivation therapy (ADT). � Novel antihormonal therapy in combination with ADT seems a plausible option among patients with newly diagnosed metastatic hormone-sensitive prostate cancer and docetaxel can be safely postponed until later lines in a subset of patients with low tumor burden after the control of the pandemic. Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, Phase III trial Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled Phase III study	./cache/cord-338251-r31xh0fw.txt	./txt/cord-338251-r31xh0fw.txt